BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17167037)

  • 1. Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.
    Sheppard NC; Davies SL; Jeffs SA; Vieira SM; Sattentau QJ
    Clin Vaccine Immunol; 2007 Feb; 14(2):157-67. PubMed ID: 17167037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
    J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF
    J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O; Tilley SA
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
    Derby NR; Gray S; Wayner E; Campogan D; Vlahogiannis G; Kraft Z; Barnett SW; Srivastava IK; Stamatatos L
    Virology; 2007 Sep; 366(2):433-45. PubMed ID: 17560621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation, characterization and cross-reactivities of monoclonal antibodies against the p24 core protein and the gp130 envelope glycoprotein of HIV-2ben.
    Faisst AC; Otteken A; Nick S; Hunsmann G
    Med Microbiol Immunol; 1993 Jul; 182(3):119-28. PubMed ID: 7694060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
    Srivastava IK; Stamatatos L; Kan E; Vajdy M; Lian Y; Hilt S; Martin L; Vita C; Zhu P; Roux KH; Vojtech L; C Montefiori D; Donnelly J; Ulmer JB; Barnett SW
    J Virol; 2003 Oct; 77(20):11244-59. PubMed ID: 14512572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.
    Gao F; Scearce RM; Alam SM; Hora B; Xia S; Hohm JE; Parks RJ; Ogburn DF; Tomaras GD; Park E; Lomas WE; Maino VC; Fiscus SA; Cohen MS; Moody MA; Hahn BH; Korber BT; Liao HX; Haynes BF
    Virology; 2009 Nov; 394(1):91-8. PubMed ID: 19744690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
    Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
    J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.
    Eugene HS; Pierce-Paul BR; Cragio JK; Ross TM
    Virol J; 2013 Apr; 10():102. PubMed ID: 23548077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.
    Liao HX; Tsao CY; Alam SM; Muldoon M; Vandergrift N; Ma BJ; Lu X; Sutherland LL; Scearce RM; Bowman C; Parks R; Chen H; Blinn JH; Lapedes A; Watson S; Xia SM; Foulger A; Hahn BH; Shaw GM; Swanstrom R; Montefiori DC; Gao F; Haynes BF; Korber B
    J Virol; 2013 Apr; 87(8):4185-201. PubMed ID: 23365441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.